3SOF

Sir Joke: I agree. Unfortunately there are still more daytraders in/out of stock on daily basis than long term investors.

This stock should show a sustained upward move like XSNX but for some reason it's not.

Imagine for a moment: It would take only 450 long term investors to buy the entire float for under $8M !  If I could, I'd buy it all myself.

Obviously the SHO list of naked shorts means there is a artificially larger float, but based on what ?
What unforeseen negative news gives these shorts the balls to short it when the President of Nigeria already endorses the drug and their main source of financing took out warrants at over 10X current share price ?

Hi Gateway et al. I've been wondering if SouthEnd Stock Pickers & other promoters are still unwinding their position in XKEM since the big run up, with the assumption that no significant news is in the offing near term ?  XKEM has dropped -50% since the Mar 6th high despite additional good news.

The fact that the company's market cap of $7.2M is a trifle compared to potential long term market revs of +$500M in Nigeria according to company estimates for the lead Nicosan Sickle Cell Disease drug. Perhaps the word that production won't likely start until June (but possibly sooner) has pulled a lot of traders off to the sideline ?

Dr. Pandey, the CEO will be giving a speech at an Anti-Malarial drug conference in Africa on 3/21 but that doesn't in itself suggest any specific news would be generated out of that.

The company has several MD's & Ph'D's on staff; all with laudable career status. 450M shares outstanding, recent lawsuit win over Bristol Myers Squibb giving them $4.2M cash which allowed them to reacquire remaining interest in Nicosan from Alembic while retaining distribution rights worldwide. Paclitaxel now on the second burner and it could get white hot soon too.
Recent deal w/VCU on new heterocyclic getting Orphan Status for SCD makes XKEM the de facto leader in SCD worldwide. Production facility built, tons of raw product ready for processing into new Nicosan drug.

All the above and an extremely low market cap on a heavily shorted stock (still on the SHO's list) with great potential and endorsed by the President of Nigeria looks like a set up for a scorching stock by early summer if not early spring !

I'm not one to buy & hold penny stocks, but this one looks as tempting as any I've seen in a long while.

Your thoughts are welcomed....

Has anybody determined what the net earnings to EYII are from the sale of HYRF MARTI product ?

Gross revs mean nothing if the producer (HYRF) is making more than the reseller (EYII) off this deal.

Perhaps we need clarification here ?